Syncromune to Present Clinical Data from SV-102 Phase 1 Trial
25 Apr 2025 //
GLOBENEWSWIRE
Syncromune Appoints Zhihong Li as Chief Regulatory Affair Officer
25 Mar 2025 //
GLOBENEWSWIRE
25 Apr 2025 //
GLOBENEWSWIRE
25 Mar 2025 //
GLOBENEWSWIRE